Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 618 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Adding Sintilimab to Chemoradiotherapy Improves Event-Free Survival in Patients with High-Risk... June 24, 2024 Amivantamab Plus Lazertinib Shows Superior Efficacy to Osimertinib in First-Line Treatment... July 5, 2024 Opinion: “We’ve been pushing for change for 20 years. We’re not... January 24, 2022 Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line... July 17, 2023 Load more HOT NEWS New treatment for Waldenstrom’s macroglobulinaemia in England ¿El azúcar provoca cáncer? EMA Recommends Granting a Marketing Authorisation for Lurbinectedin New on NCI Websites for October 2018
